Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental NK cell therapy for blood cancers hits early hurdle

NCT ID NCT05839626

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, so results are limited. About 32 participants were enrolled to check safety and find the right dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID LIGHT-CHAIN AMYLOIDOSIS RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

  • HOSPITAL CLINIC i PROVINCIAL BARCELONA_Site Number : 7240003

    Barcelona, 08036, Spain

  • Het Ziekenhuisnetwerk Antwerpen vzw - ZNA Cadix_Site Number : 0560001-1

    Antwerp, 2030, Belgium

  • Het Ziekenhuisnetwerk Antwerpen vzw - ZNA Middelheim_Site Number : 0560001-2

    Antwerp, 2020, Belgium

  • Hospital Universitario Marqués de Valdecilla_Site Number : 7240001

    Santander, Cantabria, 39008, Spain

  • Institut Catala d´oncologia - Badalona_Site Number : 7240002

    Badalona, Catalonia, 08916, Spain

  • Institut Jules Bordet_Site Number : 0560002

    Anderlecht, 1070, Belgium

  • Investigational Site Number : 0360001

    Wollongong, New South Wales, 2500, Australia

  • Investigational Site Number : 0360002

    Richmond, Victoria, 3121, Australia

  • Investigational Site Number : 0560001

    Antwerp, 2060, Belgium

  • Investigational Site Number : 2030001

    Ostrava, 708 52, Czechia

  • Investigational Site Number : 2030002

    Brno, 625 00, Czechia

  • Investigational Site Number : 3480001

    Budapest, 1085, Hungary

  • Investigational Site Number : 3800001

    Rozzano, Lombardy, 20089, Italy

  • Investigational Site Number : 8260001

    Manchester, M20 4BX, United Kingdom

  • Investigational Site Number : 8260002

    London, NW1 2BU, United Kingdom

  • Investigational Site Number : 8260003

    Birmingham, B15 2TH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.